I reckon the Aviva share price is too cheap to resist. I’d buy it in an ISA today

The Aviva share price is showing signs of life as management restarts dividends and cash grows. I’d buy it in a Stocks and Shares ISA today.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Aviva (LSE: AV) share price is climbing again after years in the doldrums, but still trades at a temptingly-low valuation.

I’ve been a fan of the FTSE 100-listed insurance company for years, and it’s high on my list of companies to buy for this year’s Stocks and Shares ISA allowance. There’s a tempting opportunity here, but also a few risks.

My biggest concern is that the Aviva share price has gone nowhere in years. A decade ago, it traded at 450p. Right now, it stands 12% lower at 396p. Investors have still made good money over that period, due to Aviva’s generous dividends, but the share price is an undoubted disappointment. It looks a flop compared to rival FTSE 100 insurer Legal & General Group, which also pays generous dividends but whose share price is up 156% over 10 years.

Value trip or opportunity?

My longstanding worry is that Aviva is a classic value trap. The stock looks cheap, but it’s because management has failed to unleash its potential.

But the Aviva share price looks like it’s finally coming alive under new CEO Amanda Blanc. It’s up 37% over six months, boosted by last week’s results which showed full-year underlying operating profit of £3.2bn. That’s broadly in line with last year, despite the pandemic, which hit its core UK, Ireland and Canada businesses.

Blanc is pulling out of non-core markets, including Singapore, Vietnam and Poland. Last week, we learned that Aviva Italy is being sold for €873m. When added to the €3.2bn pocketed from selling Aviva France, the group has enjoyed a real liquidity and cash boost. It now boasts £3bn of excess capital and £3.9bn in cash.

I’m tempted by the Aviva share price

Analysts hope its cash pile could make its way to investors, in the shape of share buybacks. It could also help Aviva expand its bulk annuities business.

The good news is that dividends are restored after last year’s Covid cut. The full-year 21p is a step up from the 15.5p paid in 2019, but well down on the 30p paid in 2018. Management is looking to increase it every year, by low- to mid-single digits. The Aviva share price already offers a forward yield of 5.8% right now, with solid cover of 2.4. 

Despite the share price rebound, I think there’s still a buying opportunity here. Aviva trades at just 7.2 times forward earnings. I’d buy for the long term, as part of my retirement portfolio, and reinvest all my dividends for growth until I need to draw the income.

Top ISA dividend stock

Trimmed-down, Aviva can now focus on what it does best, although there’s still the question of whether it should separate its asset management and general insurance arms. Stock market volatility remains a risk, as does the uncertain post-Covid recovery.

Today’s low Aviva share price makes it one of the most tempting dividend growth stocks on the FTSE 100 for me.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »